The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to reach $10,367.2 million by 2031, witnessing a CAGR of 90.37% during the forecast period 2023-2031. The market growth in revenue is largely fueled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period.
Market Segmentation
• Product: BT1718, BT5528, Zilucoplan (RA101495), Rusfertide (PTG-300), PN-943
• Peptide Type: Cyclic Peptides, Disulfide-Rich Peptides (DRPs)
• Region: North America, Europe, Asia-Pacific
Regional Segmentation
• North America – U.S. and Canada
• Europe – U.K., Germany, France, Italy, and Spain
• Asia-Pacific – Japan
Market Growth Drivers
• Enhanced Binding Affinity and Cellular Uptake
• Development of Synthetic Constraining Methods
• Limitations with Conventional Peptides
• Increasing Government and Private Funding
Market Challenges
• Increased Competition from Biologics
• Risk of Immunogenic Effects and Unsatisfactory ADME Properties
Market Opportunities
• Role of Constrained Peptides in Drug Discovery
• Various Application in CNS Disease Studies and Anti-Cancer Therapy
Key Companies Profiled
Aileron Therapeutics, Inc, Bicycle Therapeutics, PLC, Polyphor Limited, Protagonist Therapeutics, Inc, Santhera Pharmaceuticals Holding, Union Chimique Belge S.A. (UCB), Pepscan Therapeutics B.V., Pepticom Ltd., PeptiDream, Inc., CPC Scientific Inc., Creative Peptides, Bio-Synthesis Inc
Request a Sample - https://bisresearch.com/requestsample?id=1195&type=download
Comments
Post a Comment